Literature DB >> 17145278

No words for feelings: alexithymia in schizophrenia patients and first-degree relatives.

Mascha van 't Wout1, André Aleman, Bob Bermond, René S Kahn.   

Abstract

OBJECTIVE: Alexithymia refers to difficulties in emotionalizing, fantasizing, verbalizing, identifying, and analyzing emotions. The goal of this study was to investigate features of alexithymia in patients with schizophrenia. In addition, we investigated if alexithymia would be associated with vulnerability to schizophrenia, by studying unaffected first-degree relatives of schizophrenia patients. Furthermore, sex differences were taken into account.
METHOD: Forty-three patients with schizophrenia, 32 unaffected siblings, and 44 healthy control subjects were compared on the Bermond-Vorst Alexithymia Questionnaire.
RESULTS: Results showed that male patients with schizophrenia, in particular, demonstrated a specific pattern of alexithymia, that is, difficulty identifying and verbalizing emotions, in the face of a higher subjective emotional arousal. Moreover, male siblings showed comparable problems in verbalizing their emotions as male patients.
CONCLUSIONS: We suggest that these difficulties in aspects underlying affect regulation could account for the deficits in social functioning observed in schizophrenia and could contribute to a greater vulnerability for schizophrenia, in particular, for males.

Entities:  

Mesh:

Year:  2007        PMID: 17145278     DOI: 10.1016/j.comppsych.2006.07.003

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  35 in total

1.  Schizotypy, alexithymia, and socioemotional outcomes.

Authors:  James P Seghers; Amanda McCleery; Nancy M Docherty
Journal:  J Nerv Ment Dis       Date:  2011-02       Impact factor: 2.254

Review 2.  Emotion processing in persons at risk for schizophrenia.

Authors:  Laura K Phillips; Larry J Seidman
Journal:  Schizophr Bull       Date:  2008-07-21       Impact factor: 9.306

3.  Altered resting state connectivity of the default mode network in alexithymia.

Authors:  Edith J Liemburg; Marte Swart; Richard Bruggeman; Rudie Kortekaas; Henderikus Knegtering; Branislava Curcić-Blake; André Aleman
Journal:  Soc Cogn Affect Neurosci       Date:  2012-05-03       Impact factor: 3.436

4.  Electrophysiological correlates of emotional responding in schizophrenia.

Authors:  William P Horan; Jonathan K Wynn; Ann M Kring; Robert F Simons; Michael F Green
Journal:  J Abnorm Psychol       Date:  2010-02

Review 5.  Anxiety in Patients with Schizophrenia: Epidemiology and Management.

Authors:  Henk Temmingh; Dan J Stein
Journal:  CNS Drugs       Date:  2015       Impact factor: 5.749

6.  The Role of Metacognitive Self-Reflectivity in Emotional Awareness and Subjective Indices of Recovery in Schizophrenia.

Authors:  Kelsey A Bonfils; Lauren Luther; Sunita George; Kelly D Buck; Paul H Lysaker
Journal:  J Nerv Ment Dis       Date:  2016-12       Impact factor: 2.254

Review 7.  Affective traits in schizophrenia and schizotypy.

Authors:  William P Horan; Jack J Blanchard; Lee Anna Clark; Michael F Green
Journal:  Schizophr Bull       Date:  2008-07-29       Impact factor: 9.306

8.  Emotion awareness and regulation in individuals with schizophrenia: Implications for social functioning.

Authors:  David Kimhy; Julia Vakhrusheva; Lauren Jobson-Ahmed; Nicholas Tarrier; Dolores Malaspina; James J Gross
Journal:  Psychiatry Res       Date:  2012-06-30       Impact factor: 3.222

Review 9.  Unique and Overlapping Symptoms in Schizophrenia Spectrum and Dissociative Disorders in Relation to Models of Psychopathology: A Systematic Review.

Authors:  Selwyn B Renard; Rafaele J C Huntjens; Paul H Lysaker; Andrew Moskowitz; André Aleman; Gerdina H M Pijnenborg
Journal:  Schizophr Bull       Date:  2016-05-21       Impact factor: 9.306

10.  Invisible side of emotions: somato-motor responses to affective facial displays in alexithymia.

Authors:  Cristina Scarpazza; Elisabetta Làdavas; Luigi Cattaneo
Journal:  Exp Brain Res       Date:  2017-11-17       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.